ArticleInternational journal of clinical pharmacy2026
Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (H. pylori) infection contributes substantially to peptic ulcer disease and gastric cancer. Increasing clarithromycin resistance has shifted guidelines towards 14-day treatment, bismuth quadruple therapy, and second-generation proton pump inhibitors (PPIs). Most studies evaluating H. pylori treatment trends reflect gastroenterologist prescribing rather than primary care.
aimThis study aimed to examine demographic differences in H. pylori eradication treatment dispensing according to sex and age group, and describe trends in eradication regimens, PPI selection, and treatment duration from 2012 to 2022 in relation to clinical guidelines. A secondary aim was to explore concomitant dispensing of multiple PPIs.
methodOur repeated cross-sectional study used a pharmacy claims database including General Medical Services (GMS) patients (~ 30% of the Irish population) from 2012 to 2022. Demographic differences (male/female; aged <45/≥45 years) in treatment dispensing were assessed using annual GMS population proportions. Annual dispensing rates were calculated for eradication regimens and PPIs. Temporal trends in PPI use and treatment duration (7 vs. 14 days) were analysed using negative binomial regression.
resultsIn total, 112,816 eradication treatments were dispensed. Annually, a higher proportion of women than men (0.46-0.65% vs. 0.40-0.60%) and individuals aged ≥ 45 than <45 years (0.64-0.81% vs. 0.26-0.46%) received treatment. Clarithromycin-amoxicillin triple therapy accounted for 72.4% of treatments, and bismuth quadruple therapy 0.1%. Esomeprazole was the most dispensed PPI (47.5%). Same-day multiple-PPI dispensing occurred on 2.7% of treatment-dispensing dates. First-generation PPI dispensing decreased 5.3% annually (incidence rate ratio [IRR] 0.95, 95% confidence interval [CI] 0.93-0.97); the second-generation annual rate change was 7.6% higher (interaction IRR 1.08, 95% CI 1.05-1.11), corresponding to a 1.9% annual increase (IRR 1.02, 95% CI 1.00-1.04). Seven-day dispensing decreased 16.2% annually (IRR 0.84, 95% CI 0.81-0.87); the annual rate change for 14-day regimens was 53.3% higher (interaction IRR 1.53, 95% CI 1.46-1.62), corresponding to a 28.5% annual increase (IRR 1.28, 95% CI 1.24-1.33).
conclusionIncreasing use of 14-day eradication treatments and esomeprazole suggests improving alignment with clinical guidelines. Continued reliance on clarithromycin-based triple therapy, minimal bismuth quadruple therapy use, and potential PPI duplication highlight opportunities for medicines optimisation.
Indexed as
Identifiers
42801398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.